{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T10:14:25Z","timestamp":1769336065649,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T00:00:00Z","timestamp":1376524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s11095-013-1145-x","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T22:54:32Z","timestamp":1376520872000},"page":"3101-3113","source":"Crossref","is-referenced-by-count":31,"title":["Bioavailability of Cinnarizine in Dogs: Effect of SNEDDS Loading Level and Correlation with Cinnarizine Solubilization During In Vitro Lipolysis"],"prefix":"10.1007","volume":"30","author":[{"given":"Anne T.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernilla","family":"\u00c5kesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jur\u00e9us","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lasse","family":"Saaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragheb","family":"Abu-Rmaileh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"M\u00fcllertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"1145_CR1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/03639040903225083","volume":"36","author":"D Attivi","year":"2010","unstructured":"Attivi D, Ajana I, Astier A, Demore B, Gibaud S. Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm. 2010;36:421\u20137.","journal-title":"Drug Dev Ind Pharm"},{"key":"1145_CR2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1208\/s12249-010-9385-0","volume":"11","author":"AR Dixit","year":"2010","unstructured":"Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech. 2010;11:314\u201321.","journal-title":"AAPS PharmSciTech"},{"key":"1145_CR3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1166\/jbn.2007.008","volume":"3","author":"S Shafiq","year":"2007","unstructured":"Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Design and development of oral oil in water ramipril nanoemulsion formulation: in vitro and in vivo assessment. J Biomed Nanotechnol. 2007;3:28\u201344.","journal-title":"J Biomed Nanotechnol"},{"key":"1145_CR4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/pharmaceutics4040641","volume":"4","author":"AT Larsen","year":"2012","unstructured":"Larsen AT, Ogbonna A, Abu-Rmaileh R, Abrahamsson B, \u00d8stergaard J, Mullertz A. SNEDDS containing poorly water soluble cinnarizine; development and in vitro characterization of dispersion, digestion and solubilization. Pharmaceutics. 2012;4:641\u201365.","journal-title":"Pharmaceutics"},{"key":"1145_CR5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejps.2012.11.004","volume":"48","author":"AT Larsen","year":"2013","unstructured":"Larsen AT, Ohlsson AG, Polentarutti B, Barker RA, Phillips AR, Abu-Rmaileh R, et al. Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci. 2013;48:339\u201350.","journal-title":"Eur J Pharm Sci"},{"key":"1145_CR6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijpharm.2006.08.038","volume":"329","author":"AA Date","year":"2007","unstructured":"Date AA, Nagarsenker MS. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 2007;329:166\u201372.","journal-title":"Int J Pharm"},{"key":"1145_CR7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/nnm.10.126","volume":"5","author":"AA Date","year":"2010","unstructured":"Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine. 2010;5:1595\u2013616.","journal-title":"Nanomedicine"},{"key":"1145_CR8","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1002\/jps.23333","volume":"101","author":"N Marasini","year":"2012","unstructured":"Marasini N, Yan YD, Poudel BK, Choi HG, Yong CS, Kim JO. Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function. J Pharm Sci. 2012;101:4584\u201396.","journal-title":"J Pharm Sci"},{"key":"1145_CR9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejpb.2012.03.005","volume":"81","author":"R Holm","year":"2012","unstructured":"Holm R, Tonsberg H, Jorgensen EB, Abedinpour P, Farsad S, Mullertz A. Influence of bile on the absorption of halofantrine from lipid-based formulations. Eur J Pharm Biopharm. 2012;81:281\u20137.","journal-title":"Eur J Pharm Biopharm"},{"key":"1145_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2012.02.027","volume":"160","author":"N Thomas","year":"2012","unstructured":"Thomas N, Holm R, Mullertz A, Rades T. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release. 2012;160:25\u201332.","journal-title":"J Control Release"},{"key":"1145_CR11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1208\/s12248-012-9433-7","volume":"15","author":"N Thomas","year":"2012","unstructured":"Thomas N, Holm R, Garmer M, Karlsson JJ, Mullertz A, Rades T. Supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J. 2012;15:219\u201327.","journal-title":"AAPS J"},{"key":"1145_CR12","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/jps.20403","volume":"94","author":"M Grove","year":"2005","unstructured":"Grove M, Pedersen GP, Nielsen JL, Mullertz A. Bioavailability of seocalcitol I: relating solubility in biorelevant media with oral bioavailability in rats - effect of medium and long chain triglycerides. J Pharm Sci. 2005;94:1830\u20138.","journal-title":"J Pharm Sci"},{"key":"1145_CR13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2004.06.013","volume":"99","author":"GA Kossena","year":"2004","unstructured":"Kossena GA, Charman WN, Boyd BJ, Porter CJ. A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs. J Control Release. 2004;99:217\u201329.","journal-title":"J Control Release"},{"key":"1145_CR14","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s11095-008-9641-0","volume":"25","author":"A Larsen","year":"2008","unstructured":"Larsen A, Holm R, Pedersen ML, Mullertz A. Lipid-based formulations for danazol containing a digestible surfactant, labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm Res. 2008;25:2769\u201377.","journal-title":"Pharm Res"},{"key":"1145_CR15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0928-0987(01)00182-8","volume":"14","author":"NH Zangenberg","year":"2001","unstructured":"Zangenberg NH, Mullertz A, Kristensen HG, Hovgaard L. A dynamic in vitro lipolysis model II: evaluation of the model. Eur J Pharm Sci. 2001;14:237\u201344.","journal-title":"Eur J Pharm Sci"},{"key":"1145_CR16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1211\/jpp.62.04.0008","volume":"62","author":"B Polentarutti","year":"2010","unstructured":"Polentarutti B, Albery T, Dressman J, Abrahamsson B. Modification of gastric pH in the fasted dog. J Pharm Pharmacol. 2010;62:462\u20139.","journal-title":"J Pharm Pharmacol"},{"key":"1145_CR17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/dmd.105.008615","volume":"34","author":"J Rautio","year":"2006","unstructured":"Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006;34:786\u201392.","journal-title":"Drug Metab Dispos"},{"key":"1145_CR18","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/jps.22122","volume":"99","author":"K Kleberg","year":"2010","unstructured":"Kleberg K, Jacobsen F, Fatouros DG, Mullertz A. Biorelevant media simulating Fed State intestinal fluids: colloid phase characterization and impact on solubilization capacity. J Pharm Sci. 2010;99:3522\u201332.","journal-title":"J Pharm Sci"},{"key":"1145_CR19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","volume":"175","author":"P Artursson","year":"1991","unstructured":"Artursson P, Karlsson J. Correlation between oral-drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (caco-2) cells. Biochem Biophys Res Commun. 1991;175:880\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"1145_CR20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320.","journal-title":"Pharm Res"},{"key":"1145_CR21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/mp100049m","volume":"7","author":"JH Fagerberg","year":"2010","unstructured":"Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, Bergstrom CA. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol Pharm. 2010;7:1419\u201330.","journal-title":"Mol Pharm"},{"key":"1145_CR22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jps.20780","volume":"96","author":"PP Constantinides","year":"2007","unstructured":"Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro\/in vivo case studies. J Pharm Sci. 2007;96:235\u201348.","journal-title":"J Pharm Sci"},{"key":"1145_CR23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","volume":"278","author":"G Cornaire","year":"2004","unstructured":"Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm. 2004;278:119\u201331.","journal-title":"Int J Pharm"},{"key":"1145_CR24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1248\/bpb.19.1511","volume":"19","author":"S Kariya","year":"1996","unstructured":"Kariya S, Isozaki S, Uchino K, Suzuki T, Narimatsu S. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996;19:1511\u20134.","journal-title":"Biol Pharm Bull"},{"key":"1145_CR25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1006\/bbrc.1993.1761","volume":"193","author":"S Narimatsu","year":"1993","unstructured":"Narimatsu S, Kariya S, Isozaki S, Ohmori S, Kitada M, Hosokawa S, et al. Involvement of Cyp2D6 in oxidative-metabolism of cinnarizine and Flunarizine in human liver-microsomes. Biochem Biophys Res Commun. 1993;193:1262\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1145_CR26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6\u201313.","journal-title":"Pharmacogenomics J"},{"key":"1145_CR27","first-page":"1133","volume":"27","author":"SK Paulson","year":"1999","unstructured":"Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos. 1999;27:1133\u201342.","journal-title":"Drug Metab Dispos"},{"key":"1145_CR28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2:875\u201394.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1145_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF03190396","volume":"26","author":"R Schmidt","year":"2001","unstructured":"Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R. Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2001;26:193\u2013200.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1145_CR30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jps.2600840306","volume":"84","author":"T Jarvinen","year":"1995","unstructured":"Jarvinen T, Jarvinen K, Schwarting N, Stella VJ. Beta-cyclodextrin derivatives, Sbe4-beta-Cd and Hp-beta-Cd. Increase the oral bioavailability of cinnarizine in beagle dogs. J Pharm Sci. 1995;84:295\u20139.","journal-title":"J Pharm Sci"},{"key":"1145_CR31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2009.06.001","volume":"379","author":"SF Han","year":"2009","unstructured":"Han SF, Yao TT, Zhang XX, Gan L, Zhu CL, Yua HZ, et al. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Int J Pharm. 2009;379:18\u201324.","journal-title":"Int J Pharm"},{"key":"1145_CR32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1023\/B:PHAM.0000036914.22132.cc","volume":"21","author":"CJH Porter","year":"2004","unstructured":"Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004;21:1405\u201312.","journal-title":"Pharm Res"},{"key":"1145_CR33","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11095-007-9363-8","volume":"24","author":"GA Kossena","year":"2007","unstructured":"Kossena GA, Charman WN, Wilson CG, O\u2019Mahony B, Lindsay B, Hempenstall JM, et al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res. 2007;24:2084\u201396.","journal-title":"Pharm Res"},{"key":"1145_CR34","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1002\/jps.22226","volume":"99","author":"PJ Sassene","year":"2010","unstructured":"Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades T, et al. Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. J Pharm Sci. 2010;99:4982\u201391.","journal-title":"J Pharm Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-013-1145-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1145-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:54:38Z","timestamp":1559354078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-013-1145-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s11095-013-1145-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,15]]}}}